Thor Industries shares gain 5% after Q4 sales beat estimates
- U.S. stocks traded mixed on Tuesday; Nasdaq rose 0.51% to 27,259.09, Dow fell 0.31% to 51,889.27, S&P 500 gained 0.10% to 7,772.79
- Thor Industries shares gained around 5% after Q4 sales of $2.312 billion beat the analyst estimate of $2.168 billion, though EPS of 78 cents missed the 96-cent consensus
- Decoy Therapeutics surged 144% and Quanome Technologies rose 72%, while Compass Therapeutics fell 25% and Celldex Therapeutics dropped 15%
- Oil fell 1.4% to $94.45; gold down 0.3% at $4,369.80; silver down 0.1% to $66.345; copper up 1.4% to $6.8595
- The Federal Reserve's Fifth District manufacturing index fell to -2 in September from 4 the prior month, missing the market estimate of 5

*this image is generated using AI for illustrative purposes only.
U.S. stocks traded mixed on Tuesday, with the Nasdaq Composite climbing 0.51% to 27,259.09, while the Dow Jones Industrial Average fell 0.31% to 51,889.27 and the S&P 500 rose 0.10% to 7,772.79.
Thor Industries leads headlines after Q4 results
Shares of Thor Industries rose around 5% on Tuesday after the company reported its fourth-quarter results. The company posted quarterly earnings of 78 cents per share, missing the analyst consensus estimate of 96 cents per share. Quarterly sales of $2.312 billion beat the analyst consensus estimate of $2.168 billion.
Sector performance
Communication services shares led gains, rising 1.2% on Tuesday. Financial stocks were the laggard, falling 2%.
Equities on the move
Several stocks saw sharp moves on Tuesday. The following companies recorded notable gains:
| Company | Move | Price | Catalyst |
|---|---|---|---|
| Viking Therapeutics Inc | +26% | $37.88 | Top-line results from maintenance study of VK2735 |
| Decoy Therapeutics Inc | +144% | $6.24 | Refined corporate strategy to explore D-MAVs for additional candidates |
| Quanome Technologies, Inc | +72% | $1.10 | Purchase and Sale Agreement with Compal Electronics for 32 GPU server units |
On the downside, several stocks declined sharply:
| Company | Move | Price | Catalyst |
|---|---|---|---|
| Celldex Therapeutics Inc | -15% | $32.18 | Topline results from Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 trials for barzolvolimab in chronic spontaneous urticaria |
| Compass Therapeutics Inc. | -25% | $1.36 | FDA recommended a survival benefit trial before a Biologics License Application for tovecimig in biliary tract cancer |
| Xanadu Quantum Technologies Ltd | -17% | $6.08 | No specific catalyst disclosed |
Commodities
Oil fell 1.4% to $94.45, while gold traded down 0.3% at $4,369.80. Silver declined 0.1% to $66.345, while copper rose 1.4% to $6.8595.
Global markets
European shares closed higher. The eurozone's STOXX 600 climbed 0.4%; Spain's IBEX 35 Index rose 0.7%; Germany's DAX gained 0.2%; France's CAC 40 rose 0.4%; and London's FTSE 100 slipped 0.1%.
Asian markets closed mixed on Tuesday. Hong Kong's Hang Seng index rose 0.18%, China's Shanghai Composite gained 0.06%, and India's BSE Sensex fell 0.44%.
Economic data
- The U.S. Redbook Index rose 7.6% year-over-year in the week ending Sept. 19.
- The Federal Reserve's Fifth District manufacturing index declined to -2 in September, compared to 4 in the previous month, versus market estimates of 5.
How might the divergence between Thor Industries' revenue beat and earnings miss influence investor sentiment toward other consumer discretionary stocks in the upcoming earnings season?
What are the potential regulatory or clinical development timelines for Compass Therapeutics following the FDA's recommendation for an additional survival benefit trial?
How could the sharp decline in financial sector performance, coupled with mixed global markets, impact expectations for upcoming Federal Reserve policy decisions?

























